- Joined
- Jan 4, 2005
- Messages
- 779
- Reaction score
- 3
So what did you all think about the article in NEJM Feb 28, 2008, and the accompanying editorial from Dr. Parillo?
Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. NEJM Vol 358 No. 9 877-87 2008
My view: Yet another piece of proof that vasopresson potentiates the effects of catecholamine vasopressors. I thought it leaves the question in the title still, well, quite open for debate.
Wish we could have a large, multi-center, prospective, blinded trial comparing norepi vs. phenyl vs. dopa vs. vaso!
Oh, and some problems with the actual study in question:
1) Were the patients really that sick? Consider the (relatively) low mortality rate, and the baseline pressure of MAPs in the low 70s.
2) The treatment window was 12h. This needs to be shorter....
Any other comments?
Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. NEJM Vol 358 No. 9 877-87 2008
My view: Yet another piece of proof that vasopresson potentiates the effects of catecholamine vasopressors. I thought it leaves the question in the title still, well, quite open for debate.
Wish we could have a large, multi-center, prospective, blinded trial comparing norepi vs. phenyl vs. dopa vs. vaso!
Oh, and some problems with the actual study in question:
1) Were the patients really that sick? Consider the (relatively) low mortality rate, and the baseline pressure of MAPs in the low 70s.
2) The treatment window was 12h. This needs to be shorter....
Any other comments?